2024

1. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

   Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

   Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

3. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

   Clinical Genitourinary Cancer, Vol. 22, Núm. 5

4. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

   EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

5. Evolving SARS-CoV-2 severity among hospital and university affiliates in Spain and Greater Boston

   Enfermedades Infecciosas y Microbiologia Clinica

6. Global cross-sectional survey on neonatal pharmacologic sedation and analgesia practices and pain assessment tools: impact of the sociodemographic index (SDI)

   Pediatric Research

7. Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?

   European Journal of Internal Medicine, Vol. 119, pp. 13-30

8. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

   ESMO Open, Vol. 9, Núm. 9

9. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

10. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

11. Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 619-630

12. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

13. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial

    Chest, Vol. 165, Núm. 3, pp. 673-681

14. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

15. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

16. Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study

    Open Forum Infectious Diseases

17. Targeting bacterial polysaccharides with antibodies and vaccines

    Methods in Microbiology (Academic Press Inc.), pp. 173-223

18. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Overview and Summary

    Cancer Cytopathology, Vol. 132, Núm. 7, pp. 396-418

19. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer

20. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711